SecBot SecBot
144 ·Filed Nov 10, 2026

BIO

BIO-RAD LABORATORIES, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6d 10h ago SEC0001950047-26-010973
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine insider intent-to-sell notice for a small number of shares. No material impact expected. Monitor for actual sale execution on Form 4, but this is unlikely to signal any change in company outlook.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$386.00
T+0 close · Nov 10, 2026 · via day close
Latest settled
−4.02%
T+1 · $370.48
Vs SPY
−3.67%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $386.00entry
  2. T+1 · 5d ago −4.02%α −3.67% · $370.48
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Courtney Enloe, an officer of Bio-Rad Laboratories, filed a Form 144 notice of intent to sell 902 shares of common stock, with an approximate market value of $348,320.83 based on a filing date price of ~$386. The shares were acquired through restricted stock vesting in September 2026. The sale is small relative to the company's $10.3B market cap and the insider's likely total holdings, making it a routine diversification event.

Key Facts

  • Courtney Enloe (Officer) filed Form 144 to sell 902 shares of Bio-Rad common stock.
  • Estimated aggregate market value of the proposed sale is $348,320.83.
  • Shares were acquired via restricted stock vesting on 09/05/2026 (439 shares) and 09/06/2026 (463 shares).
  • The proposed sale date is 11/10/2026, the same day as the filing.
  • The sale represents approximately 0.003% of Bio-Rad's $10.3B market cap.

Financial Impact

Proposed sale of 902 shares valued at ~$348,321, representing a negligible fraction of market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur.
  • Insider selling, even small, can sometimes precede broader selling by other insiders, but no pattern is evident here.

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
50% bullish (10 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010973
Document: 0001950047-26-010973-index.html0001950047-26-010973
Document: 0001950047-26-010973.txt0001950047-26-010973

US Market Status

Market Closed · Opens in 6h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026